Appreciating and mitigating bleeding risk

Circulation

Volumn 125, Issue 14, 2012, Pages

  Freedman, Jane E ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; CORTICOSTEROID; NEW DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PRASUGREL; WARFARIN;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; BLEEDING; CARDIOVASCULAR DISEASE; DRUG MEGADOSE; DRUG SAFETY; HEART INFARCTION; HEMOPHILIA; HUMAN; LOW DRUG DOSE; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SCORING SYSTEM; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THROMBOSIS;

HEMORRHAGE; HUMANS; RISK;

EID: 84859528362     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.112.104224     Document Type: Review

References (14)

1. Hagedorn I, Schmidbauer S, Pleines I, Kleinschnitz C, Kronthaler U, Stoll G, Dickneite G, Nieswandt B. Factor XIIa inhibitor recombinant human albumin infestin-4 abolishes occlusive arterial thrombus for-mation without affecting bleeding. Circulation. 2010;121:1510-1517.
2. Lauer A, Cianchetti FA, Van Cott EM, Schlunk F, Schulz E, Pfeilschifter W, Steinmetz H, Schaffer CB, Lo EH, Foerch C. Anticoagulation with the oral direct thrombin inhibitor dabigatran does not enlarge hematoma volume in experimental intracerebralhemorrhage. Circulation. 2011;124: 1654-1662.
3. Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, Oldgren J, Yang S, Alings M, Kaatz S, Hohnloser SH, Diener HC, Franzosi MG, Huber K, Reilly P, Varrone J, Yusuf S. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation oflong-term anticoagulant therapy (RE-LY) trial. Circulation. 2011;123: 2363-2372.
4. Hochholzer W, Wiviott SD, Antman EM, Contant CF, Guo J, Giugliano RP, Dalby AJ, Montalescot G, Braunwald E. Predictors of bleeding and time dependence of association of bleeding with mor-tality: insights from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Throm-bolysis in Myocardial Infarction 38 (TRITON-TIMI 38). Circulation. 2011;123:2681-2689.
5. Garcia Rodriguez LA, Lin KJ, Hernandez-Diaz S, Johansson S. Risk of upper gastrointestinal bleeding with low-dose acetylsalicylic acid alone and in combination with clopidogrel and other medications. Circulation. 2011;123:1108-1115.
6. Berger PB, Bhatt DL, Fuster V, Steg PG, Fox KA, Shao M, Brennan DM, Hacke W, Montalescot G, Steinhubl SR, Topol EJ. Bleeding compli-cations with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Man-agement, and Avoidance (CHARISMA) trial. Circulation. 2010;121: 2575-2583.
7. Subherwal S, Bach RG, Chen AY, Gage BF, Rao SV, Newby LK, Wang TY, Gibler WB, Ohman EM, Roe MT, Pollack CV Jr, Peterson ED, Alexander KP. Baseline risk of major bleeding in non-st-segment-elevation myocardial infarction: the CRUSADE (Can Rapid Risk Strati-fication of Unstable angina patients Suppress ADverse outcomes with Early Implementation of the ACC/AHA guidelines) bleeding score. Circulation. 2009;119:1873-1882.
8. Abu-Assi E, Gracia-Acuna JM, Ferreira-Gonzalez I, Pena-Gil C, Gayoso-Diz P, Gonzalez-Juanatey JR. Evaluating the performance of the can rapid risk stratification of unstable angina patients suppress adverse outcomes with early implementation of the acc/aha guidelines (crusade) bleeding score in a contemporary Spanish cohort of patients with non-ST-segment elevation acute myocardial infarction. Circulation. 2010;121:2419-2426.
9. Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, Kaul S, Wiviott SD, Menon V, Nikolsky E, Serebruany V, Valgimigli M, Vranckx P, Taggart D, Sabik JF, Cutlip DE, Krucoff MW, Ohman EM, Steg PG, White H. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the bleeding academic research consortium. Circulation. 2011;123:2736-2747.
10. Hicks KA, Stockbridge NL, Targum SL, Temple RJ. Bleeding academic research consortium consensus report: the Food and Drug Administration perspective. Circulation. 2011;123:2664-2665.
11. Hackam DG, Woodward M, Newby LK, Bhatt DL, Shao M, Smith EE, Donner A, Mamdani M, Douketis JD, Arima H, Chalmers J, Macmahon S, Tirschwell DL, Psaty BM, Bushnell CD, Aguilar MI, Capampangan DJ, Werring DJ, De Rango P, Viswanathan A, Danchin N, Cheng CL, Yang YH, Verdel BM, Lai MS, Kennedy J, Uchiyama S, Yamaguchi T, Ikeda Y, Mrkobrada M. Statins and intracerebral hemorrhage: collab-orative systematic review and meta-analysis. Circulation. 2011;124: 2233-2242.
12. Violi F, Pignatelli P, Basili S. Nutrition, supplements, and vitamins in platelet function and bleeding. Circulation. 2010;121:1033-1044.
13. Palmerini T, Mehran R, Dangas G, Nikolsky E, Witzenbichler B, Guagliumi G, Dudek D, Genereux P, Caixeta A, Rabbani L, Weisz G, Parise H, Fahy M, Xu K, Brodie B, Lansky A, Stone GW. Impact of leukocyte count on mortality and bleeding in patients with myocardial infarction undergoing primary percutaneous coronary interventions: analysis from the Harmonizing Outcome with Revascularization and Stent in Acute Myocardial Infarction trial. Circulation. 2011;123: 2829-2837.
14. Sibbing D, Koch W, Gebhard D, Schuster T, Braun S, Stegherr J, Morath T, Schomig A, von Beckerath N, Kastrati A. Cytochrome 2c19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation. 2010;121:512-518.